Trials / Completed
CompletedNCT04493827
Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 114 (actual)
- Sponsor
- Central Hospital, Nancy, France · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The recent discovery of oncogenic drivers has revolutionized the management of advanced lung cancer by development of tyrosine kinase inhibitors targeted therapies. Prevalence of daily tobacco use is evaluated at 31,3 % in Grand-Est region, the only French region with a statistically significative difference for smoking habits. This region shows a higher incidence (+ 13 %) and mortality for lung cancer in comparison to the average for other French regions. The objectives of our studie were to estimate the distribution of oncogenic drivers and analyse their prognostic impacts in the Nancy University Hospital Center metastatic lung adenocarcinoma's population.
Conditions
- Adenocarcinoma of Lung Stage IV
- Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in, Somatic
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2019-12-01
- Completion
- 2019-12-01
- First posted
- 2020-07-30
- Last updated
- 2020-07-30
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04493827. Inclusion in this directory is not an endorsement.